[go: up one dir, main page]

WO2008078729A1 - 溶出性改善方法 - Google Patents

溶出性改善方法 Download PDF

Info

Publication number
WO2008078729A1
WO2008078729A1 PCT/JP2007/074784 JP2007074784W WO2008078729A1 WO 2008078729 A1 WO2008078729 A1 WO 2008078729A1 JP 2007074784 W JP2007074784 W JP 2007074784W WO 2008078729 A1 WO2008078729 A1 WO 2008078729A1
Authority
WO
WIPO (PCT)
Prior art keywords
dissolution property
improving dissolution
azelnidipine
olmesartan medoxomil
improving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/074784
Other languages
English (en)
French (fr)
Inventor
Ikumasa Ohno
Ryoichi Hayakawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2008551107A priority Critical patent/JP5241512B2/ja
Publication of WO2008078729A1 publication Critical patent/WO2008078729A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

オルメサルタンメドキソミル及びアゼルニジピンを含有する固形製剤の溶出性改善方法を提供する。 オルメサルタンメドキソミルとアゼルニジピンが互いに接触しないように分離配合する。
PCT/JP2007/074784 2006-12-26 2007-12-25 溶出性改善方法 Ceased WO2008078729A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008551107A JP5241512B2 (ja) 2006-12-26 2007-12-25 溶出性改善方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006349474 2006-12-26
JP2006-349474 2006-12-26

Publications (1)

Publication Number Publication Date
WO2008078729A1 true WO2008078729A1 (ja) 2008-07-03

Family

ID=39562518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074784 Ceased WO2008078729A1 (ja) 2006-12-26 2007-12-25 溶出性改善方法

Country Status (4)

Country Link
JP (1) JP5241512B2 (ja)
KR (1) KR20090094285A (ja)
TW (1) TWI488658B (ja)
WO (1) WO2008078729A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107081A1 (ja) * 2009-03-19 2010-09-23 第一三共株式会社 包装により安定保存された固形製剤
JP2011225537A (ja) * 2010-03-31 2011-11-10 Daiichi Sankyo Co Ltd 固形製剤の製造方法
JP2014224099A (ja) * 2013-04-15 2014-12-04 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
JP2015511635A (ja) * 2012-03-30 2015-04-20 デウン ファーマシューティカル カンパニー リミテッド オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067003A1 (ja) * 2003-01-31 2004-08-12 Sankyo Company, Limited 動脈硬化及び高血圧症の予防及び治療のための医薬
JP2006298764A (ja) * 2005-04-15 2006-11-02 Sankyo Co Ltd 高血圧症治療に有用な複合体
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW585786B (en) * 1998-07-28 2004-05-01 Takeda Chemical Industries Ltd Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition
US20060034913A1 (en) * 2004-08-13 2006-02-16 James Gaede Multiplex drug delivery device
PT1814527E (pt) * 2004-11-05 2014-01-16 Boehringer Ingelheim Int Comprimido de bicamada compreendendo telmisartan e amlodipina
BRPI0612674B8 (pt) * 2005-06-27 2021-05-25 Daiichi Sankyo Co Ltd preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067003A1 (ja) * 2003-01-31 2004-08-12 Sankyo Company, Limited 動脈硬化及び高血圧症の予防及び治療のための医薬
JP2006298764A (ja) * 2005-04-15 2006-11-02 Sankyo Co Ltd 高血圧症治療に有用な複合体
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATSUMOTO M.: "Yakuzaigaku Manual", vol. 1ST ED., 1989, NANZANDO CO., LTD., HAKKO, pages: 114 *
OKANO T.: "Shin.Yakuzaigaku Soron", vol. 3RD ED., 1987, NANOKODO CO., LTD., HAKKO, pages: 134 - 145 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107081A1 (ja) * 2009-03-19 2010-09-23 第一三共株式会社 包装により安定保存された固形製剤
JPWO2010107081A1 (ja) * 2009-03-19 2012-09-20 第一三共株式会社 包装により安定保存された固形製剤
JP2011225537A (ja) * 2010-03-31 2011-11-10 Daiichi Sankyo Co Ltd 固形製剤の製造方法
JP2015511635A (ja) * 2012-03-30 2015-04-20 デウン ファーマシューティカル カンパニー リミテッド オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
JP2014224099A (ja) * 2013-04-15 2014-12-04 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物

Also Published As

Publication number Publication date
TW200835525A (en) 2008-09-01
TWI488658B (zh) 2015-06-21
JPWO2008078729A1 (ja) 2010-04-30
JP5241512B2 (ja) 2013-07-17
KR20090094285A (ko) 2009-09-04

Similar Documents

Publication Publication Date Title
MX285041B (es) Composiciones de combustible que contienen farnesano y derivados de farnesano y metodo de preparacion y uso de estas.
WO2008005705A3 (en) Metal-containing formulations and methods of use
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
GB0903844D0 (en) Solid dosage form of olmesartan medoxomil and amlodipine
SI2044076T1 (sl) Postopek za pripravo azenapina in vmesni produkti, uporabljeni v tem postopku
IL207792A0 (en) Methods, dosage forms, and kits for administering ziprasidone without food
WO2008027600A3 (en) Imatinib compositions
EP1993322A4 (en) ULTRASOUND SENSOR, AND METHOD OF MANUFACTURING SAME
WO2008078726A1 (ja) 固形製剤
WO2010069335A3 (en) Diagnosis of endometritis
WO2008078729A1 (ja) 溶出性改善方法
WO2008156645A3 (en) Pharmaceutical compositions and uses
WO2008021135A8 (en) Syneretic composition, associated method and article
WO2007099555A3 (en) Pharmaceutical tablet compositions containing irbesartan
EP2074258A4 (en) FIBER PLATES, THEIR MANUFACTURE AND USE
WO2009053742A3 (en) Salts of nefopam and their use in therapy
WO2007098924A3 (de) Zusammensetzung umfassend ein mittel zum stabilisieren von wirkstoffen im trinkwasser und eine brausemischung, verfahren zu deren herstellung und deren verwendung
WO2009113091A3 (en) Pharmaceutical compositions comprising valsartan
WO2008078727A1 (ja) 溶出性の改善された医薬組成物
WO2008073317A3 (en) Cytarabine for treatment of glioma
GB2435262B (en) Method, composition and articles
GB0607562D0 (en) Method, composition and use
BRPI0818783A2 (pt) Método de preparação de (6r)-3-hexil-4-hidróxi-6-undecil-5,6-diidropirano-2-ona, e intermediário empregado no método
WO2008074461A3 (de) Fluoreszenz-nanopartikel
GB201018110D0 (en) Solid dosage form of olmesartan medoxomil, amiodipine and hydrochlorothiazide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860013

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008551107

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020097012652

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07860013

Country of ref document: EP

Kind code of ref document: A1